A systemic approach to cancer treatment: Tumor cell reprogramming focused on endocrine-related cancers

Current Medicinal Chemistry

Volumn 21, Issue 9, 2014, Pages 1072-1081

  Biava, P M ^a   Nicolini, A ^b   Ferrari, P ^b   Carpi, A ^b   Sell, S ^c  

^a IRCCS MULTIMEDICA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Cancer; Cancer stem cells; Differentiation factors; Embryonic microenvironment; Epigenetic reprogramming; Reprogramming of cancer cells; Stem cells

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; BIOLOGICAL FACTOR; CASPASE 3; PROTEIN P53; PROTEIN P73; RETINOBLASTOMA PROTEIN; STEM CELL DIFFERENTIATION STAGE FACTOR; TELOMERASE; TRANSCRIPTION FACTOR; TRANSCRIPTOME; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL EMBRYO; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL STRAIN MCF 7; DENDRITIC CELL; EMBRYONIC STEM CELL; ENDOCRINE TUMOR; EPIGENETICS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LOW DRUG DOSE; MAT 8 GENE; MEDICAL TECHNOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEAR REPROGRAMMING; OOCYTE DONATION; OVARY CARCINOMA; PHENOTYPE; PROSTATE CANCER; STEM CELL; SYSTEMIC THERAPY; TUMOR CELL LINE; TUMOR GENE; TUMOR MICROENVIRONMENT; UMBILICAL CORD MATRIX DERIVED STEM CELL;

ANIMALS; CELL DIFFERENTIATION; ENDOCRINE SYSTEM; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; NUCLEAR REPROGRAMMING; TUMOR MICROENVIRONMENT;

EID: 84896368413     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666131201143124     Document Type: Article

References (145)

1. Biava, P. M.; Bonsignorio, D. Cancer and cell differentiation: a model to explain malignancy. J. Tumor Marker Oncol., 2002, 17, 47-54.
2. Einhorn, L. Are there factors preventing cancer development during embryonic life? Oncodev. Biol. Med., 1982, 4, 219-229. (Pubitemid 13151173)
3. Brent, R. L. Radiation Teratogenesis. Teratology, 1980, 21, 281-298. (Pubitemid 10043104)
4. Pierce, G. B. The cancer cell and its control by the embryo. Am. J. Pathol., 1983, 113, 116-124.
5. Yu, C. L.; Tsai, M. H. Fetal fetuin selectively induces apoptosis in cancer cell lines and shows anti-cancer activity in tumor animal models. Cancer Lett., 2001, 166, 173-184.
6. Brinster, R. L. The effect of cells transferred into the mouse blastocyst on subsequent development. J. Exp. Med., 1974, 140, 1049-1056.
7. Minz, B.; Illmensee, K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl. Acad. Sci. USA, 1975, 72, 3585-3589.
8. Papaioannou, V. E.; McBurney, M. V.; Gardner, R. L.; Evans, R. L. Fate of teratocarcinoma cells injected into early mouse embryos. Nature, 1975, 258, 70-73.
9. Pierce, G. B.; Lewis, S. H.; Miller, G. J.; Moritz, E.; Miller, P. Tumorigenicity of embryonal carcinoma as an essay to study control of malignancy by the murine blastocyst. Proc. Natl. Acad. Sci. USA, 1979, 76, 6649-6651. (Pubitemid 10163457)
10. Pierce, G. B.; Podesta', A.; Wells, R. S. The role of the blastocyst trophoderm in control of colony formation. In: Silver S, Strickland S, Martin G (eds) Teratocarcinoma Stem Cells, Cold Spring Harbor Laboratory, 1983, New York, pp 15-22.
11. Gershenson, M.; Graves, K.; Carson, D.; Wells, R. S.; Pierce, G. B. Regulation of melanoma by the embryonic skin. Proc. Natl. Acad. Sci. USA, 1986, 83, 7307-7310. (Pubitemid 16000510)
12. Pierce, G. B.; Pantazis, C. G.; Caldwell, J. E.; Wells, R. S. Specificity of the control of tumor formation by blastocyst. Cancer Res., 1982, 42, 1082-1087. (Pubitemid 12141223)
13. Webb, C. W.; Gootwine, E.; Sachs, L. Developmental potential of myeloid leukemia cells injected into rat midgestation embryos. Dev. Biol., 1984, 101, 221-224.
14. Weaver, V.; Petersen, O.; Wang, F.; Larabell, C.; Briand, P.; Damsky, C.; Bissel, M. Reversion of the malignant phenotype of human breast cancer in three-dimensional culture and in vivo by integrin bloking bodies. J. Cell Biol., 1997, 137, 231-245. (Pubitemid 27167310)
15. Coleman, W. B.; Wennerberg, A. E.; Smith, G. J.; Grishman, J. W. Regulation of differentiation of diploid and some aneuploid rat liver epithelial (stemlike) cells by the hepatic microenvironment. Am. J. Pathol., 1993, 142, 1373-1382. (Pubitemid 24058124)
16. Postovit, L. M.; Maragaryan, N. V.; Seftor, E. A.; Kirschmann, D. A.; Lipavski, A.; Wheaton, W. W.; Abbott, D. E.; Seftor, R. E.; Hendrix, M. J. Human embryonic stem cell microenvironment suppress the tumorigenic phenotype of aggressive cancer cells. Proc. Natl. Acad. Sci. USA, 2008, 18, 105-111.
17. Lee, M. L.; Seftor, E. A.; Bonde, G.; Cornell, R. A.; Hendrix, M. J. The fate of human malignant melanoma cells transplanted into Zebrafish embryos: assessment of migration and cell division in the absence of tumor formation. Dev. Dyn., 2005, 200, 1560-1570. (Pubitemid 40995154)
18. Topczewska, J. M.; Postovit, L. M.; Margaryan, N. V.; Sam, A.; Hess, A. R.; Wheaton W. W.; Nickoloff, B. J.; Topczewki, J.; Hendrix, M.j. Embryonic and tumorogenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat. Med., 2006, 12, 925-932. (Pubitemid 44175144)
19. Hendrix, M. J.; Seftor, E. A.; Seftor, R. E. B.; Kaisermeier-Kulesa, J.; Kulesa, P. M.; Postovit, L. M. Reprogramming metastatic tumor cells with embryonic microenvironment. Nat. Rev. Cancer, 2007, 7, 246-255. (Pubitemid 46480969)
20. Kulesa, P. M.; Kaisermeier-Kulesa, J. C.; Teddy, J. M.; Margaryan, N. V.; Seftor, E. A.; Hendrix, M. J. Reprogramming metastatic tumor cells to assume a neural crest like phenotype in a embryonic microenvironment. Proc. Natl. Acad. Sci. USA, 2006, 103, 3752-3757. (Pubitemid 43376627)
21. Wells, R. S.; Miotto, K. A. Widespread inhibition of neuroblastoma cells in the 13-to 17-day old mouse embryo. Cancer Res., 1986, 46, 1659-1662. (Pubitemid 16121486)
22. Podesta, A. N.; Mullins, J.; Pierce, G. B.; Sell, R. S. The nerula state mouse embryos in control of neuroblastoma. Proc. Natl. Acad. Sci. USA., 1984, 81, 7608-7611. (Pubitemid 15196233)
23. McKinnel, R. G.; Deggins, B. A.; Labat, D. D. Transplantation of pluripotential nuclei from triploid frog tumors. Science, 1969, 165, 394-396.
24. Li, L; Connelly, M. C.; Wetmore, C.; Currant, T.; Morgan, J. I. Mouse embryos cloned from brain tumors. Cancer Res., 2003, 63, 2733-2737
25. Gootwine, E.; Webb, C. G.; Sachs, L. Participation of myeloid leukemia cells injected into embryos in haematopoietic differentiation in adult mice. Nature, 1982, 299, 63-65. (Pubitemid 12049769)
26. Biava, P. M.; Fiorito, A.; Negro, C.; Mariani, M. Effect of treatment with embryonic and uterine tissue homogenates on Lewis lung carcinoma development. Cancer Lett., 1988, 41, 265-270.
27. Biava, P. M.; Bonsignorio, D.; Hoxa, M. (2000) Life-Protecting Factor (LPF): an anti-cancer low molecular weight fraction isolated from pregnant uterine mucosa during embryo organogenesis. J. Tumor Marker Oncol., 2000, 15, 223-233.
28. Biava, P. M.; Bonsignorio, D.; Hoxha, M.; Impagliazzo, M.; Frosi, A.; Larese, F.; Negro, C. (2002) Mother-embryo cross-talk: the anti-cancer substances produced by mother and embryo during cell differentiation. A review of experimental data. J. Tumor Marker Oncol., 2002, 17, 55-58.
29. Dalerba, P.; Cho, R. W.; Clarke. M. F. Cancer stem cells: models and concepts. Annu. Rev. Med., 2007, 58, 267-284. (Pubitemid 46706514)
30. Lee, J. T.; Herlyn, M. Embryogenesis meet tumorigenesis. Nat. Med., 2006, 12, 882-883.
31. Katoh, M.; Katoh, M. Transcriptional regulation of WNT2B based on the balance of Hedgehog, Notch, BMP and WNT signals. Int. J. Oncol., 2009, 34, 1411-1415.
32. Kathoh, M.; Katoh, M. Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and Notch signaling cascades. Int. J. Mol. Med., 2009, 23, 763-769.
33. Peifer, M.; Polakis, P. WNT signaling in oncogenesis and embryogenesis: a look outside the nucleus. Science, 2000, 287, 1606-1609. (Pubitemid 30127755)
34. Chritofk, H. F.; Vander Heiden, M. G.; Harris, M. H.; Ramanathan, A.; Gerszten, R. E.; Wei, R.; Fleming, M. D.; Schreiber, S. L.; Cantley, L. C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumor growth. Nature, 2008, 452, 230-233. (Pubitemid 351380249)
35. Mani, S. A.; Guo, W.; Liao, M.; Eaton, E.; Ayyanan, A.; Zhou, A.; Brooks, M.; Reinhard, F.; Zhang, C.; Shipitsin, M. M. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 2008, 133, 704-715. (Pubitemid 351636299)
36. Carro, M. S.; Lim, W. K.; Javier Alvares, M.; Bollo, R. J.; Zhao, X.; Snyder, E. Y.; Sulman, E. P.; Anne, S. L.; Doetsch, F.; Colman, H.; Lasorella, A.; Adape, K; Califano, A.; Iavarone, A. The transcriptional network for mesenchymal transformation of brain tumor. Nature, 2010, 463, 318-325.
37. Mima, K.; Hayashy, H.; Kuroki, H.; Nagakagawa, S.; Okabe, H.; Chikamoto, A.; Watanabe, M.; Beppu, T.; Baba, H. Epithelialmesenchimal transition expression profiles as a prognostic factors for disease-free survival in hepatocellular carcinoma: clinical significance of trasforming growth factor-beta signaling. Oncol. Lett., 2013, 1, 149-154.
38. Sell, S.; Pierce, G. B. Biology of Disease: Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab. Invest., 1994, 70, 6-21
39. Link, V.; Shevchenko, A.; Heisember, CP. Proteomics of early Zebrafish embryos. BCM Dev. Biol., 2006, 6, 1-9.
40. Tuan Leng Tay.; Quingsong Lin.; Teck Keong Seow.; Keng Hwa Tan.; Choy Leong Hew.; Zhiyang Gong. (2006) Proteomic analysis of protein profiles during early development of the Zebrafish - Danio Rerio. Proteomics, 2006, 6, 3176-3188. (Pubitemid 43806413)
41. Biava, P. M.; Bonsignorio, D.; Hoxa, M. Cell proliferation curves of different human tumor lines after in vitro treatment with Zebrafish embryonic extracts. J. Tumor Marker Oncol., 2001, 16, 195-202.
42. Biava, P. M.; Carluccio, A. Activation of anti-oncogene p53 produced by embryonic extracts in vitro tumor cells. J. Tumor Marker Oncol., 1997, 12, 9-15. (Pubitemid 127806874)
43. Biava, P. M.; Bonsignorio, D.; Hoxa, M.; Facco, R.; Ielapi, T.; Frati, L.; Bizzarri, M. Post-traslational modification of the retinoblastoma protein (pRb) induced by in vitro administration of Zebrafish embryonic extracts on human kidney adenocarcinomacell line. J. Tumor Marker Oncol., 2002, 17, 59-64.
44. Cucina, A.; Biava, P. M.; D'Anselmi, F.; Coluccia, P.; Conti, F.; Di Clemente, R.; Miccheli, A.; Frati, L.; Gulino, A.; Bizzarri, M. Zebrafish embryo proteins induce apoptosis in human colon cancer cells (Caco2). Apoptosis, 2006, 9, 1617-1628. (Pubitemid 44253678)
45. D'Anselmi, F.; Cucina, A.; Biava, P. M.; Proietti, S.; Coluccia, P.; Frati, L.; Bizzarri, M. Zebrafish stem cell differentiation stage factors suppress Bcl-xL release and enhance 5 Fu mediated apoptosisin colon cancer cells. Curr. Pharm. Biotechnol., 2011, 12, 261-267.
46. Biava, P. M.; Bonsignorio, D.; Impagliazzo, M.; Frosi, A.; Larese, F.; Negro, C.; Hermann, G. F.; Matarese, S.; Malzac, J.; Pontiggia, P. Embryonic differentiation factors with anticancer properties: preliminary clinical results in the therapy for advanced tumors. J. Tumor Marker Oncol., 2002, 17(3), 65-69.
47. Livraghi, T.; Meloni, F.; Frosi, A.; Lazzaroni, S.; Bizzarri, M.; Frati, L.; Biava, P. M. Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma: an open randomized clinical trial. Oncol. Res., 2005, 15, 399-408. (Pubitemid 43198597)
48. Park, Y. J.; Claus, R.; Weichenhan, D.; Plass, C. Genome-wide epigenetic modifications in cancer. Prog. Drug Res., 2011, 67, 25-49.
49. Lo, P. K.; Sukumar, S. Epigenomic and breast cancer. Pharmacogenomics, 2008, 9, 1879-1902.
50. Novak, P.; Jensen, T. J.; Garbe, J. G.; Stampfer, M. R.; Futcher, B. W. Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. Cancer Res., 2009, 69, 5251-5258.
51. Hinselwood, R. A.; Clark, S. J. Breast cancer epigenetics: normal human mammary epithelial cells as a model system. Journal Mol. Med., 2008, 86, 1315-1328.
52. Tommasi, S.; Karm, D. L.; Wu, X.; Yen, Y.; Pfeifer, G. P. Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res., 2009, 11(1), R14.
53. Allegrucci, C.; Rushton, M. D.; Dixon, J. E.; Sottile, V.; Shah, M.; Kumari, R.; Watson, S.; Alberio, R.; Johnson, A. D. Epigenetic reprogramming of breast cancer with oocyte extracts. Mol. Cancer, 2011, 10(1), 7.
54. Rachakatia, R. S.; Troyer, D. Wharton's jelly stromal cells as potential delivery vehicles for cancer therapeutics. Future Oncol., 2009, 5(8), 1237-1244.
55. Ayuzawa, R.; Doi, C.; Rachakatia, R. S.; Pyle, M. M.; Maurya, D. K.; Troyer, D.; Tamura, M. Naive Human umbical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. Cancer Lett., 2009, 280(1), 31-37.
56. Ganta, C.; Chiyo, D.; Ayuzawa, R.; Rachakatia, R. S.; Pyle, M.; Andrews, G.; Weiss, M.; Tamura, M.; Troyer, D. Rat umbical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation. Cancer Res., 2009, 69(5), 1815-1820.
57. Uppalapati, D.; Otha, N.; Zhang, Y.; Kawabata, A.; Pyle, M. M.; Becker, K. G.; Troyer, D.; Tamura, M. Identification and characterization of unique tumoricidal genes in rat umbical cord matrix stem cells. Mol. Pharm., 2011, 8(5), 1549-1558.
58. Bae, K. M.; Su' Z.; Frye, C.; McClellan, S.; Allan, R. W.; Andrejewsky, J. T.; Kelley, V.; Jorgensen, M.; Steindler, D. A.; Vieweg, J.; Siemann, DW. Espression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J. Urol., 2010, 183(5), 2045-2053.
59. Xu, T.; Xu, Y.; Liao, C. P.; Lau, R.; Goldkorn, A. Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo. Mol. Cancer Ther., 2010, 9(2), 438-449.
60. Xu, T.; He, K.; Wang, L.; Goldkorn, A; Prostate tumor cells with cancer progenitors properties have high telomerase activity and are rapidly killed by telomerase interference. Prostate, 2011, 71(13), 1390-4000.
61. Xu, Y.; He, K.; Goldkorn, A. Telomerase targeted therapy in cancer and cancer stem cells. Clin. Adv. Hematol. Oncol., 2011, 9(6), 442-455.
62. Grzmil, M.; Voigt, S.; Thelen, P.; Hemmerlein, B.; Helke, K.; Burfeind, P. Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells. Int. J. Oncol., 2004, 24(1), 97-105.
63. Rivenbark, A. G.; Stolzenburg, S.; Beltran, A. S.; Yuan, X.; Rots, M. G.; Strahl, B. D.; Blancafort, P. Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics, 2012, 7(4), 350-360.
64. Stolzenburg, S.; Rots, M. G.; Beltran, A. S.; Rivenbark, A. G.; Yuan, X.; Quian, H.; Strahl, B. D.; Blankfort, P. Targeting silencing of the oncogenic transcription factors SOX2 in breast cancer. Nucleic Acids Res., 2012, 40(14), 6725-6740.
65. Cubilloz-Ruiz, J. R.; Baird, J. R.; Tesone, A. J.; Rutkowky, M. R.; Scarlett, U. K.; Camposeco-Jacobs, A. L.; Anandon-Arnillas, J.; Harwood, N. M.; Koro, M.; Fiering, S. N.; Sempere, L. F.; Cornejo-Garcia, J. R. Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res., 2012, 72(7), 1683-1693.
66. Quinn, M. C.; Filali-Mouhim, A.; Provencher, D. M.; Mess-Masson, A. M.; Tonin, P. M. Reprogramming of transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer. Mol. Carcinog., 2009, 48(7), 648-661.
67. Park, Y. J.; Claus, R.; Weichenhan, D.; Plass, C. Genome-wide epigenetic modifications in cancer. Prog. Drug Res., 2011, 67, 25-49.
68. Han, W. C.; Counter, C. M.; Lundberg, A. S.; Beijersbergen, R. L.; Brooks, M. W.; Weinberg, R. A. Creation of human tumor cells with defined genetic elements. Nature, 1999, 400, 464-468. (Pubitemid 29361801)
69. Olumi, A. F.; Grossfeld, G. D.; Hayward, S. W.; Carrol, P. R.; Tisty T. D., Cunha, G. R. Carcinoma associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res., 1999, 59, 5002-5011. (Pubitemid 29472907)
70. Skobe, M.; Fusening, N. E. Tumorigenic conversion of immortal keratinocytes trough stromal cell activation. Proc. Natl. Acad. Sci. USA, 1998, 95, 1050-1055. (Pubitemid 28124910)
71. Coussens, L. M.; Raymond, W. W.; Bergers, G.; Laig-Webster, M.; Behrendtsen, O.; Wer, Z.; Cughey, G. H.; Hanahan, D. Inflammatory mast cells up-regulation angiogenesis during squamous epithelial carcinogenesis. Genes Dev., 1999, 13, 1382-1397. (Pubitemid 29270244)
72. Hudson, J. D.; Shoabi, M. A.; Maestro, R.; Carnero, A.; Hannon, G. J.; Beach, D. H. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med., 1999, 190, 1375-1382.
73. De Palma, M.; Hanahan, D. The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol. Oncol., 2012, 6(2), 111-127.
74. Biava, P. M.; Monguzzi, A.; Bonsignorio, D.; Frosi, A.; Sell, S.; Klavins, J. V. Xenopus Laevis Embryo share antigens with Zebrafish embryos and with human malignant neoplasms. J. Tumor Marker Oncol., 2001, 16, 203-206. (Pubitemid 33793128)
75. Reya, T.; Morrison, S. J.; Clarke, M. F.; Weisman, I. L. Stem cells, cancer and cancer stem cells. Nature, 2001, 414, 105-111.
76. Sato, A.; Sakurada, K.; Kumabe, T.; Sasajima, T.; Beppu, T.; Azano, K.; Ohkuma, H.; Ogawa, A.; Mizo, K.; Tominaga, T.; Kitanaka, C.; Kayama, T. Association of stem cell marker CD133 expression with dissemination of glioblastoma. Neurosurg. Rev., 2010, 33, 175-183.
77. Di Tommaso, T.; Mazzoleni, S.; Wang, E.; Sovena, G.; Claverna, D.; Franzin, A.; Mortini, P.; Ferrone, S.; Doglioni, C.; Marincola, F. M.; Galli, R.; Parmiani, G.; Maccalli, M. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res., 2010, 16, 800-813.
78. Ji, J.; Black, K. L.; Yu, J. S. Glioma stem cell research for the development of immunotherapy. Neurosurg. Clin. N. Am., 2010, 21, 159-166.
79. Chen, J.; Chen, Z. L. Technology update for the sorting and identification of breast cancer stem cells. Chin. J. Cancer, 2010, 29, 265-269.
80. Roesler, R.; Cornelio, D. B.; Abujama, A. L.; Schwartsmann, G. HER2 as a cancer stem-cell target. Lancet Oncol., 2010, 11225-11226.
81. Wu, W. (2010) Patents related to cancer stem cell research. Recent Pat. DNA Gene Seq., 2010, 4, 40-45.
82. Park, S. Y.; Lee, H. E.; Li, H.; Shipitsin, M.; Gelman, R.; Polyak, K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Cancer Res., 2010, 16, 876-887.
83. Lawson, J. C.; Blatch, G. L.; Edkins, A. L. Cancer stem cells in breast cancer and metastasis. Cancer Res. Treat., 2009, 8, 241-254.
84. Luo, J.; Yin, X.; Ma, T.; Lu, J. Stem cells in normal mammary gland and breast cancer. Am. J. Med. Sci., 2010, 339, 366-370.
85. Spiro, S. G.; Tanner, N. T.; Silvestri, G. A.; James, S. M.; Lim, E.; Vansteenkiste, J. F.; Pirker, R. Lung cancer: progress in diagnosis staging and therapy. Respirology, 2010, 15, 44-50.
86. Gorelik, E.; Lokshin, A.; Levina, L. Lung cancer stem cells as target for therapy. Anticancer Agents Med. Chem., 2010, 10(2), 164-171.
87. Sullivan, J. P.; Minna, J. D.; Shay, J. W. Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression and targeted therapy. Cancer Metastasis. Rev., 2010, 29, 61-72.
88. Westhoff, B.; Colaluca, I. N.; D'Ario, G.; Donzelli, M.; Tosoni, D.; Volorio, G.; Pelosi, G.; Spaggiari, L.; Mazzarol, G.; Viale, G.; Pece, S.; Di Fiore, P. P. Alteration of the Notch pathway in lung cancer. Proc. Natl. Acad. Sci. USA, 2010, 87, 457-466.
89. Lawson, D. A.; Zong, Y.; Memarzadeh, S.; Xin, L.; Huang, J.; Witte, O. N. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc. Natl. Acad. Sci. USA, 2010, 7, 2610-2615.
90. Lang, S. H.; Anderson, E.; Fordham, R.; Collin, A. T. (2010) Modeling the prostate stem cell niche: an evaluation of stem cell survival and expansion in vitro. Stem Cell Rev., 2010, 19, 537-546.
91. Joung, J. Y.; Cho, K. S.; Kim, J. E.; Seo, H. K.; Ching, J.; Park, W. S.; Choi, M. K.; Lee, K. H. Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence of metastatic prostate cancer. J. Surg. Oncol., 2010, 101, 145-148.
92. Liu, T.; Cheng, W.; Lai, D.; Huang, Y.; Guo, L. Characterization of primary ovarian cancer cells in different culture systems. Oncol. Rep., 2010, 23, 1277-1284.
93. Fong, M. Y.; Kakar, S. S. The role of cancer stem cells and the side population in epithelial ovarian cancer. Histol. Histopatol., 2010, 25, 113-120.
94. Murphy, S. K. Targeting ovarian cancer initiating cells. Anticancer Agents Med. Chem., 2010, 10, 157-163.
95. Liu, M.; Mor, G.; Cheng, H.; Xiang, X.; Hui, P.; Rutheford, T.; Yin, G.; Rimm, D. L.; Holmberg, J.; Alvero, A.; Silasi, D. A. High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with the decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. Reprod. Sci., 2013, 20(5), 605-615.
96. Pen, S.; Maihle, N.. J.; Huang, Y. Pluripotency factors Lin 28 and Oct. 4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene, 2010, 29, 2153-2159.
97. Kusumbe, A. P.; Bapat, S. A. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res., 2009, 69, 9245-9253.
98. Tomuleasa, C.; Soritau, O.; Rus-Ciuca, D.; Pop, T.; Todea, D.; Mosteanu, O.; Pintea, B.; Foris, V.; Susman, S.; Kacso, G.; Irimie, A. Isolation and characterization of hepatic cells with stem-like properties from hepatocellular carcinoma. J. Gastrointestin. Liver Dis., 2010, 19, 61-67.
99. Zou, G. M. Liver cancer stem cells as an important target in liver cancer therapies. Anticancer Agents Med. Chem., 2010, 10, 172-175.
100. Lee, T. K.; Castilho, A.; Ma, S.; Ng, I. O. Liver cancer stem cells: implication for new therapeutic target. Liver Int., 2009, 29, 955-965.
101. Marquardt, J. U.; Thorgeirsson, S. S. Stem Cells in hepatocarcinogenesis: evidence from genomic data. Semin. Liver Dis., 2010, 30, 26-34.
102. Kung, J. W.; Currie, I. S.; Forbes, S. J.; Ross, J. A. Liver development, regeneration, and carcinogenesis. J. Biomed. Biotechnol., 2010, 30, 26-34.
103. Gai, H.; Nguyen, D. M.; Moon, Y. J.; Aguila, J. R.; Fink, L. M.; Ward, D. C.; Ma, Y. Generation of murine hepatic lineage cells from induced pluripotent stem cells. Differentiation, 2010, 79, 171-181.
104. Correia, M.; Machado, J. C.; Ristimaki, A. Basic aspects of gastric cancer. Helicobacter, 2009, 14, 36-40.
105. Takaishi, S.; Okumura, T.; Tu, S.; Wang, S. S.; Shibata, W.; Vigneshwaran, R.; Gordon, S. A.; Shimada, Y.; Wang, T. C. Identification of gastric cancer stem cells using the surface marker CD44. Stem Cells, 2009, 59, 106-120.
106. Nishii, T.; Yashiro, M.; Shinto, O.; Sawada, Y.; Ohira, M.; Hirakawa, K. Cancer stem cell-like SP cells have a high adhesion ability to the peritoneum in gastric carcinoma. Cancer Sci., 2009, 100, 1397-1402.
107. Chen, Z.; Xu, W. R.; Quian, H.; Zhu, W.; Bu, X. F.; Wang, S.; Yan, Y. M.; Mao, F.; Gu, H. B.; Cao, H. L.; Xu, X. J. Oct4 a novel marker for human gastric cancer. J. Surg. Oncol., 2009, 34, 1201-1207.
108. Kang, D. H.; Han, M. E.; Song, M. H.; Lee, Y. S.; Kim, E. H.; Kim, H. J. Kim, G. H. Kim, D. H.; Yoon, S.; Baek, S. Y.; Kim, B. S.; Kim, G. B.; Oh, S. O. The role of hedgehog signaling during gastric regeneration. J. Gastroenterol., 2009, 44, 372-379.
109. Yeung, T. M.; Ghandhi, S. C.; Wilding, J. L.; Muschel, R.; Bodmer, W. F. Cancer stem cells from colorectal cancer derived cell lines. Proc. Natl. Acad. Sci. USA, 2010, 107, 3722-3727.
110. Gulino, A.; Ferretti, E.; De Smaele, E. Hedgehog signaling in colon cancer and stem cells. EMBO Mol. Med., 2009, 1, 300-302.
111. Thenappen, A.; Li, Y.; Shetty, K.; Johnson, L.; Reddy, E. P.; Mishra, L. New therapeutic targeting colon cancer stem cells. Curr. Colorectal Cancer Rep., 2009, 5, 209.
112. Rasheed, Z. A.; Yang, J.; Wang, Q.; Kowalski, J.; Freed, I.; Murter, C.; Hong, S. M.; Koorstra, J. B.; Rajeshkumar, N. V.; He, X.; Goggins, M.; Iacobuzio-Donahue, C.; Berman, D. M.; Laheru, D.; Jimeno, A.; Hidalgo, M.; Maitra, A.; Matsui, W. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J. Natl. Cancer Inst., 2010, 102, 340-351.
113. Puri, S.; Hebrok, M. Cellular plasticity within pancreas-lessons learned from development. Dev. Cell, 2010, 18, 342-356.
114. Quante, M.; Wang, T. C. Stem cells in gastroenterology and hepatology. Nat. Rev. Gastroenterol. Hepatol., 2009, 6, 724-737.
115. Ailles, L.; Prince, M. Cancer stem cells in head and neck squamous cell carcinoma. Methods Mol. Biol., 2009, 568, 175-193.
116. Zhang, P.; Zhang, Y.; Mao, L.; Zhang, Z.; Chen, W. Side population in oral squamous cell carcinoma possesses tumor stem cell phenotype. Cancer Lett., 2009, 277, 227-234.
117. Brunner, M.; Thurnher, D.; Heiduschka, G.; Grasl, M. C. H.; Brostjan, C.; Erovic, B. M. Elevated levels of circulating endothelial progenitor cells in head and neck cancer patients. J. Surg. Oncol., 2008, 98, 545-550.
118. Zhang, Q.; Shi, S.; Yen, Y.; Brown, J.; Ta, J. Q.; Le, A. D. A subpopulation of CD133 (+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett., 2010, 289, 151-160.
119. Waddington, C. H. Cancer and theory of organizers. Nature, 1935, 135, 606-608.
120. Needham, J. New advances in the chemistry and biology of organized growth. Proc. R. Soc. Lond. Biol. Sci., 1936, 29, 1577-1626
121. Ruiz-Vela, A.; Aguillar-Gallardo, C.; Simon, C. Building a framework for embryonic microenvironments and cancer stem cells. Stem Cell Rev., 2009, 5, 319-327.
122. Kenny, P. A.; Bissel, M. J. Tumor reversion: correction of malignant behaviour by microenvironmental cues. Int. J. Cancer, 2003, 107, 688-695. (Pubitemid 37339720)
123. Diez-Torre, A.; Andrade, R.; Eguizabal, C.; Lopez, E.; Arluzea, J.; Siliò, M.; Aréchaga, L. Reprogramming of melanoma cells by embryonic microenvironment. Int. Dev. Biol., 2009, 53, 1563-1568.
124. Huang, S.; Ernberg, I.; Kauffman, S. Cancer attractors. A system view of tumors from a gene network dynamics and developmental perspectives. Semin. Cell Dev. Biol., 2009, 20, 869-876.
125. Guo, Y.; Eichler, G. S.; Feng, Y.; Ingberg, D. E.; Huang, S. Towards a holistic; yet gene-centered analysis of gene expression profiles: a case study of human lung cancers. J. Biomed. Biotechnol., 2006, 69141.
126. Su, A. L.; Wiltshire, T.; Batalo, S.; Lapp, H.; Ching, K. A.; Block, D. A. Gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl. Acad. Sci. USA, 2004, 101, 6062-6067. (Pubitemid 38520528)
127. Hendrix, M. J.; Seftor, E. A.; Seftor, R. B.; Kasermaier-Kulesa, J.; Kulesa, P. M.; Postoviz, L. M. Reprogramming metastatic tumor cells with embryonic microenvironment. Nat. Rev. Cancer, 2007, 7, 246-255. (Pubitemid 46480969)
128. Wu, V. Modulation of micro RNA for potential cancer therapeutic. Methods Mol. Biol., 2011, 676, 59-70.
129. Onder, T. T.; Daley, G. Q. MicroRNAs become macroplayers in somatic cell reprogramming. Genome Med., 2011, 3, 40.
130. Abollo-Jiménez, F.; Jiménez, R.; Cobaleda, C. Physiological cellular reprogramming and cancer. Semin. Cancer Biol., 2010, 20, 98-106.
131. Spike, B. T.; Wahl, G. M. p53, stem cells and reprogramming: tumor suppression beyond guarding the genome. Genes Cancer, 2011, 2, 404-419.
132. Zhao, T.; Xu, Y. p53 and stem cells: new development and new concern. Trends Cell Biol., 2010, 20, 170-175.
133. Teperek-Tkacz, M.; Pasque, V.; Gentsch, G.; Ferguson-Smith, A. Epigenetic reprogramming-is deamination key to active DNA demethylation? Reproduction, 2011, 142, 621-632.
134. Zhang, Y.; Moriguchi, H. Chromatin remodelling system, cancer stem-like attractors and cellular reprogramming. Cell Mol. Life Sci., 2011, 68, 3557-3571.
135. Chik, F.; Szyh, M.; Rabbani, S. A. Role of epigenetic in cancer inhibition and progression. Adv. Exp. Med. Biol., 2011, 720, 91-104.
136. Xu, Y.; He, K; Goldkorn, A. Telomerase targeted therapy in cancer and cancer stem cells. Clin. Adv. Hematol. Oncol., 2011, 9, 442-455.
137. Schumacker, P. T. SIRT3 controls cancer metabolic reprogramming by regulating ROS and HIF. Cancer Cell, 2011, 19, 299-230.
138. Bizzarri, M.; Cucina, A.; Biava, P. M.; Proietti, S.; D'Anselmi, F.; Dinicola, S.; Pasqualeto, A.; Lisi, E. Embryonic morphogenetic field induce phenotipic reversion in cancer cells. Curr. Pharm. Biotechnol., 2011, 12(2), 243-253.
139. Biava, P. M. Reprogramming of normal and cancer stem cells. Curr. Pharm. Biotechnol., 2011, 12(2), 145.
140. Biava, P. M.; Basevi, M.; Biggiero, L.; Borgonovo, A.; Borgonovo, E.; Burigana, F. Cancer cell reprogramming: stem cell differentiation stage factors and an agent based model to optimize cancer treatment. Curr. Pharm. Biotechnol., 2011, 12(2), 231-242.
141. Biava, P. M. The use of stem cell differentiation stage factors in controlling tumor growth. A new model of Cancer. J. Tumor Marker Oncol., 2005, 20(3), 109.
142. Sell S. Cancer and Stem Cell Signaling: A Guide to Preventive and Therapeutic Strategies for Cancer Stem Cells. Stem Cell Rev., 2007, 3, 1-6. (Pubitemid 47472807)
143. Freeman, JA.; Espinosa JM. The impact of post-transcriptional regulation in the p53 network. Briefing in Functional Gen., 2012, 12(1), 46-57.
144. Sell S. Leukemia: Stem cells, maturation arrest, and differentiation therapy. Stem Cell. Rev., 2005, 1, 197-205.
145. Hanahan, D.; Weinberg, R. A. Hallmarrk of cancer: the next generation. Cell, 2011, 144, 646-674.